Tamoxifen 10mg

Tamoxifen 10 mg

Brand: Magnus Pharmaceuticals
Content: 100 tablets | 10 mg per tablet
Price: €29
Manufactured in: Europe

🧪 Product Overview

Tamoxifen 10 mg delivers a high-purity selective estrogen receptor modulator (SERM) used extensively in both endocrine and androgen-focused research. By binding to ER-α/β receptors and blocking estrogen-mediated feedback on the hypothalamic–pituitary–gonadal (HPG) axis, tamoxifen promotes a cascade increase in LH, FSH, and endogenous testosterone in male models.

In female models, it remains the gold-standard anti-estrogen for ER-positive tumor protocols. Its high oral bioavailability (~100%) and long half-life (4–11 days for parent, up to 70 hours for active metabolite endoxifen) support once-daily use in long-range studies, including PCT, fertility, gynecomastia reversal, and hormone-modulation assays.

✅ Key Research Highlights

HPG-axis stimulation:
10–20 mg/day for 3 months doubled serum testosterone in hypogonadal males [PMC]

Gynecomastia control:
Clinical data show significant breast tissue regression in AAS-using males on 10–20 mg/day

Anti-estrogen benchmark:
First-line SERM for ER+ breast cancer research and comparative estrogen-blocking trials [NCBI]

Pharmacokinetics:
~100% oral bioavailability; 4–11 day half-life (parent), 50–70 hours (endoxifen metabolite) [Wikipedia]

Storage & stability:
Film-coated tablets stable ≤25 °C with 36-month shelf-life — ideal for long-term protocols [PubChem, PubMed]

🧬 Suggested Laboratory Applications

HPG-axis and testosterone recovery models

Gynecomastia reversal and estrogenic side-effect prevention

SERM benchmarking in ER-positive breast-cancer assays

Post-cycle therapy research for anabolic models

Hormone-modulation pharmacokinetics

📊 Technical Specifications

Field	Data
Chemical Name	Tamoxifen (base); supplied as Tamoxifen Citrate
Chemical Formula	C26H29NO (base)
Synonyms	Nolvadex; TMX; 4-(1-dimethylaminoethoxy)-diphenyl-1-ethenyl-phenol
Molecular Weight	371.5 g/mol (base); 563.6 g/mol (citrate)
CAS Number	10540-29-1 (base); 54965-24-1 (citrate)
Half-life	Parent: 4–11 days · Endoxifen: 50–70 hours
Detection Window	Long-acting — detectable for several weeks
Documented Benefits	↑ LH/FSH, ↑ testosterone, ↓ gynecomastia, SERM gold standard
Main Risks	Hot-flushes, ↓ bone density, cataract risk, thrombo-embolism, lipid shifts
Total Active Compound	1,000 mg tamoxifen base per carton (10 mg × 100 tablets)
Shelf-life	36 months (manufacturer specification)

❄️ PubChem-Supported Research Insights

Blocks estrogen feedback to HPG axis → ↑ endogenous testosterone

Used clinically in both male infertility and female ER+ oncology

Demonstrated ability to reverse steroid-induced gynecomastia

Maintains receptor suppression up to 6 weeks post-use

Oral form preferred over injectable SERMs for logistical ease

⚠️ Documented Research Side Effects

Hot-flushes, fatigue, and temporary visual disturbances

Lipid profile changes (↑ LDL / ↓ HDL) with long-term use

Thrombo-embolic events in susceptible models

Cataract formation risk at extended exposure

Reduced bone-mineral density (BMD) with prolonged protocols

🧯 Handling & Compliance

For Research Use Only — Not for human or veterinary use
Store at 15–25°C, protect from light and moisture
Purchase confirms qualified researcher status
Listed on WADA Prohibited List S4 (Hormone Modulators) — any exposure may trigger positive test